Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2020
Bellicum Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

(State or other jurisdiction
of incorporation)
File Number)
(IRS Employer
Identification No.)
2130 W. Holcombe Blvd., Ste. 800, Houston, TX 77030
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: 832-384-1100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareBLCMThe Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

M.D. Anderson Manufacturing Activities

The University of Texas M.D. Anderson Cancer Center (“M.D. Anderson”) notified Bellicum Pharmaceuticals, Inc. (the “Company”) of its decision to resume, on a phased basis, selected research and manufacturing activities, including activity in the manufacturing facility in which the product candidates for the Company’s clinical development programs are manufactured. The Company is providing this update in light of its April 17, 2020 disclosure announcing that M.D. Anderson had informed the Company of its decision to temporarily halt such research and manufacturing activities. Whether M.D. Anderson continues manufacturing without interruption or again temporarily halts activity in its effort to mitigate the impact of COVID-19 on its patients and employees is within the sole discretion of M.D. Anderson.

Dismissal of Securities Litigation

On May 29, 2020, the U.S. District Court for the Southern District of Texas, Houston Division granted the Company’s motion to dismiss with prejudice in the purported class action complaint filed on February 6, 2018 against the Company and certain of its current and former employees, captioned Nipun Kakkar v. Bellicum Pharmaceuticals, Inc., Rick Fair and Alan Musso. As previously reported, the complaint alleged that the Company and members of its management violated federal securities laws by making allegedly false and misleading statements. The court’s written order dismissed the case in its entirety with prejudice, resulting in a termination of all claims. The plaintiffs have not indicated whether they will appeal the dismissal.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Bellicum Pharmaceuticals, Inc.
Dated: June 2, 2020
/s/ Richard A. Fair
Richard A. Fair
President and Chief Executive Officer

May 29, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 29, 2020
Entity Registrant Name Bellicum Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36783
Entity Tax Identification Number 20-1450200
Entity Address, Address Line One 2130 W. Holcombe Blvd.
Entity Address, Address Line Two Ste. 800
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77030
City Area Code 832
Local Phone Number 384-1100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol BLCM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001358403
Amendment Flag false